Report Sections

See All Reports

  • HP:0002110: Bronchiectasis
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002110: Bronchiectasis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug2914 SELF-BREATHE Wiki 0.58
    drug619 COVID-19 infection status Wiki 0.58
    drug380 BRII-196 Wiki 0.58
    Name (Synonyms) Correlation
    drug567 COVI-AMG Wiki 0.58
    drug2448 Placebo Wiki 0.05

    Correlated MeSH Terms (11)


    Name (Synonyms) Correlation
    D001987 Bronchiectasis NIH 1.00
    D001469 Barotrauma NIH 0.58
    D004646 Emphysema NIH 0.58
    Name (Synonyms) Correlation
    D017093 Liver Failure NIH 0.58
    D003550 Cystic Fibrosis NIH 0.33
    D017563 Lung Diseases, Interstitial NIH 0.31
    D000755 Anemia, Sickle Cell NIH 0.29
    D008171 Lung Diseases, NIH 0.25
    D004417 Dyspnea NIH 0.18
    D011024 Pneumonia, Viral NIH 0.06
    D011014 Pneumonia NIH 0.03

    Correlated HPO Terms (5)


    Name (Synonyms) Correlation
    HP:0001399 Hepatic failure HPO 0.58
    HP:0006515 Interstitial pneumonitis HPO 0.31
    HP:0002088 Abnormal lung morphology HPO 0.25
    Name (Synonyms) Correlation
    HP:0002098 Respiratory distress HPO 0.18
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia

    Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and invasive mechanical ventilation (IMV). Main purpose of this study is to evaluate with non invasive clinical instruments (pletysmography, Diffusion lung capacity for carbon monoxide -DLCO-, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) the development of medium-to-long term pulmonary sequelae caused by SARS-CoV-2 pneumonia.

    NCT04435327
    Conditions
    1. COVID
    2. Pneumonia, Viral
    3. Barotrauma
    4. Interstitial Lung Disease
    5. Bronchiectasis Adult
    6. Emphysema
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Bronchiectasis Lung Diseases, Interstitial Emphysema Barotrauma
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T1 at 6 months from discharge

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T2 at 12 months from discharge

    Secondary Outcomes

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV,%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: Modified Medical Research Council - mMRC > 0 (minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T1 at 6 months from discharge

    Description: Modified Medical Research Council - mMRC > 0(minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T2 at 12 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T1 at 6 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T2 at 12 months from discharge

    Description: Presence and extension of radiological alterations at chest X-ray

    Measure: Presence and extension of radiological alterations at chest X-ray

    Time: T1 at 6 months from discharge

    Description: Presence and extension of radiological alterations at chest CT scan

    Measure: Presence and extension of radiological alterations at chest CT scan

    Time: T2 at 12 months from discharge
    2 COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic

    In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

    NCT04487873
    Conditions
    1. Covid19
    2. Bronchiectasis
    MeSH:Bronchiectasis
    HPO:Bronchiectasis

    Primary Outcomes

    Description: COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.

    Measure: COVID-19 Phobia

    Time: 5 minutes

    Description: Quality of life was evaluated with Nottingham Health Profile

    Measure: Qol

    Time: 10 minutes

    Secondary Outcomes

    Description: Health anxiety was evaluated with Health Anxiety Inventory

    Measure: Health anxiety

    Time: 10 minutes

    Description: Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    Measure: Physical activity

    Time: 5 minutes

    Description: Quality of sleep was evaluated with Pittsburgh Sleep Quality Index

    Measure: Quality of sleep

    Time: 10 minutes
    3 A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

    A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

    NCT04574050
    Conditions
    1. Cancer
    2. COPD
    3. Asthma
    4. Bronchiectasis Adult
    5. Interstitial Lung Disease
    6. Cystic Fibrosis
    7. Chronic Heart Failure
    8. Sickle Cell Disease
    9. Renal Failure
    10. Liver Failure
    11. Post COVID-19
    12. Dyspnea
    Interventions
    1. Other: SELF-BREATHE
    MeSH:Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Bronchiectasis Lung Diseases, Interstitial Anemia, Sickle Cell
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Dyspnea Hepatic failure Interstitial pneumonitis Respiratory distress

    Primary Outcomes

    Description: The number of patients recruited into this study over a 12-month period

    Measure: Feasibility: the number of patients recruited into this study over a 12-month period

    Time: 12 months

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook